Jupiter Neurosciences Inc (JUNS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$3.41+11.80%
Close 2026-09-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put JUNS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Pursue licensing opportunities for new drug formulations: 0 licensing deals vs target of material deals by FY26.
View ThesisThis stock is volatile — it swings about 4% on a typical day and fell roughly 98% in its worst 12-month stretch.
View RiskJUNS must pursue licensing opportunities for new drug formulations to justify its price. Recent financial performance sits below its industry cohort, with no licensing deals versus a target of material deals by FY26. The company trades at a valuation below typical for its sector, with peers at the 18th percentile. This indicates that expectations may be too high given the current performance. The primary risk is the elevated miss probability of 51% for the next quarter. Peer multiples imply a price about 18% below where it trades. This read is provisional.
Trailing returns as of 2026-09-14. JUNS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare JUNS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JUNS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put JUNS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Address Nasdaq listing compliance issues
Earnings miss raises concerns about compliance and future growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.